Get the Stockscreener App
5.21
5.89%
0.29
After Hours:
5.24
0.03
+0.58%
Kalaris Therapeutics Inc stock is traded at $5.21, with a volume of 156.11K.
It is up +5.89% in the last 24 hours and down -14.73% over the past month.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
See More
Previous Close:
$4.92
Open:
$5.48
24h Volume:
156.11K
Relative Volume:
2.00
Market Cap:
$123.96M
Revenue:
-
Net Income/Loss:
$-43.44M
P/E Ratio:
-1.2419
EPS:
-4.1951
Net Cash Flow:
$-43.18M
1W Performance:
+10.85%
1M Performance:
-14.73%
6M Performance:
-19.10%
1Y Performance:
+86.74%
1-Day Range:
$5.16
$5.60
1-Week Range:
$4.56
$5.60
52-Week Range:
$2.14
$11.88
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
Name
Kalaris Therapeutics Inc
Sector
Industry
Phone
650-249-2727
Address
400 CONNELL DRIVE, BERKELEY HEIGHTS
Compare KLRS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
5.21 | 117.06M | 0 | -43.44M | -43.18M | -4.1951 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-26 | Initiated | Morgan Stanley | Overweight |
| Dec-23-25 | Initiated | Chardan Capital Markets | Buy |
| Nov-03-25 | Initiated | Citizens JMP | Mkt Outperform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Jul-23-25 | Resumed | Piper Sandler | Neutral |
| May-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-08-25 | Initiated | William Blair | Outperform |
View All
Kalaris Therapeutics Inc Stock (KLRS) Latest News
Kalaris Therapeutics director Akkaraju’s fund buys $1.18m stock By Investing.com - Investing.com Nigeria
Kalaris Therapeutics director Akkaraju’s fund buys $1.18m stock - Investing.com
Samsara entities boost control in Kalaris (KLRS) with 54.2% stake and intra-fund share deal - Stock Titan
Kalaris Therapeutics (KLRS) affiliate adds 244,300 KLRS shares - Stock Titan
Kalaris Therapeutics Inc. (KLRS) Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Disciplined SpendingSmart Trader Community - Newser
Kalaris Therapeutics (KLRS) Rallies +4.36% as Bulls Target $5.16 2026-05-20Covered Call ETF - Newser
Kalaris Therapeutics (KLRS) Falls -2.87% — Watching $4.82 Support 2026-05-15Open Signal Network - Newser
Kalaris Therapeutics (KLRS) Stock: Up +8.90%, Key Resistance at $5.52 2026-05-14MACD Signals - newser.com
Wedbush Initiates Kalaris Therapeutics at Outperform With $17 Price Target - Moomoo
Wedbush Initiates Kalaris Therapeutics(KLRS.US) With Buy Rating, Announces Target Price $17 - Moomoo
Citizens cuts Kalaris stock price target on manufacturing progress By Investing.com - Investing.com South Africa
Citizens cuts Kalaris stock price target on manufacturing progress - Investing.com
Kalaris Therapeutics Reports Q1 2026 Financial Results and Advances TH103 Clinical Trials for Retinal Diseases - Minichart
[10-Q] Kalaris Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Kalaris Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Raymond James reiterates Strong Buy on Kalaris stock amid trial progress - Investing.com Nigeria
Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates - Investing News Network
Kalaris Therapeutics posts smaller-than-expected Q1 net loss - TradingView
Kalaris Therapeutics (KLRS) posts Q1 2026 loss with $104.9M cash to fund trials into 2027 - Stock Titan
Eye drug TH103 nears dosing as Kalaris funds trials into 2027 - Stock Titan
TradingKey - TradingKey
KLRS: Kalaris Therapeutics Inc.Interactive Chart - Zacks Investment Research
KLRS Kalaris Therapeutics Q4 loss narrows more than expected, lifting shares 1.78% on positive sentiment.Financial Data - Newser
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Short Interest Update - MarketBeat
Kalaris Therapeutics Inc. (KLRS) Upgraded to Buy: Here's What You Should Know - MSN
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Kalaris Therapeutics (NASDAQ: KLRS) outlines 2026 pay and board votes - Stock Titan
Kalaris Therapeutics (NASDAQ:KLRS) Stock Price Down 3.6%What's Next? - MarketBeat
[ARS] Kalaris Therapeutics, Inc. SEC Filing - Stock Titan
Kalaris Therapeutics (KLRS) Stock: Directional Bias Review | Q4 2025: Better Than ExpectedSocial Flow Trades - Newser
KLRS (Kalaris Therapeutics Inc.) reports narrower Q4 2025 loss than expected, shares post mild gains after earnings release.Hot Momentum Watchlist - Xã Châu Thành
This Dick's Sporting Goods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Sahm
KLRS Initiated Coverage by Morgan Stanley -- Rating Set to Overw - GuruFocus
Morgan Stanley Initiates Kalaris Therapeutics at Overweight - marketscreener.com
Morgan Stanley Initiates Kalaris Therapeutics(KLRS.US) With Buy Rating, Announces Target Price $14 - 富途牛牛
Morgan Stanley initiated coverage on Kalaris Therapeutics with a new price target - Quantisnow
KLRS SEC FilingsKalaris Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
[EFFECT] Kalaris Therapeutics, Inc. SEC Filing - Stock Titan
Kalaris Therapeutics (NASDAQ: KLRS) registers $100M ATM program with TD Cowen - Stock Titan
Kalaris Therapeutics (NASDAQ: KLRS) registers 5,000,000 shares for resale - Stock Titan
Death Cross: Will Kalaris Therapeutics Inc benefit from rate cuts2026 Macro Moves & Breakout Confirmation Alerts - baoquankhu1.vn
Kalaris Therapeutics Announces CFO Resignation, Finance Leadership Shift - TipRanks
Kalaris Therapeutics IncMatthew Gall resigns as CFO effective April 14, 2026SEC filing - marketscreener.com
CFO exit at Kalaris Therapeutics (NASDAQ: KLRS) as Brett Hagen takes finance lead - Stock Titan
Volume Summary: Is Kalaris Therapeutics Inc attractive for institutional investors2026 Retail Activity & AI Enhanced Trading Alerts - baoquankhu1.vn
Kalaris Therapeutics (NASDAQ: KLRS) files $350M shelf, $100M ATM - Stock Titan
Kalaris Therapeutics (NASDAQ: KLRS) registers 5.0M shares resale prospectus - Stock Titan
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Kalaris Therapeutics Inc Stock (KLRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kalaris Therapeutics Inc Stock (KLRS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hagen Brett R | Chief Accounting Officer |
Mar 20 '26 |
Sale |
6.72 |
1,915 |
12,869 |
0 |
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):